P2.06-32 YB-1 - A Key Factor in Mesothelioma Aggressive Growth and Behaviour

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1287
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P2.06-16 YB-1: An Important Driver of Mesothelioma Drug Resistance and a Potential Novel Therapeutic Target

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P2.06-13 Poor Nutritional Status Is a Poor Prognostic Factor in Malignant Pleural Mesothelioma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P2.06-38 Mesothelioma Stem Cells May Be the Critical Factor of Treatment Failure

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P2.06-20 Bacteria as Novel Anti-Mesothelioma Agents.

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P2.06-15 Malignant Pleural Mesothelioma in Young Adult People in Uganda

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P2.06-08 ABT-806 Derived Antibody Drug Conjugates (ADCs) Inhibit Growth of Malignant Mesothelioma In-Vivo

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P2.06-14 Does Size Matter? A Population-Based Analysis of Malignant Pleural Mesothelioma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P2.06-12 Improving Quality of Care for Pleural Mesothelioma: 2018 National Mesothelioma Audit Results for England and Wales

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Cyclooxygenase-2, Epidermal Growth Factor Receptor, and Aromatase Signaling in Inflammation and Mesothelioma

Molecular Cancer Therapeutics
Cancer ResearchOncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy